ACTH(4-10) comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.
Scientific literature on semax is unevenly distributed. A substantial share of published work originates from a small number of laboratories in Russia, while independent replication elsewhere is limited. Human data consist mostly of small trials with short follow-up, and several reported outcomes rely on subjective rating scales. Questions about how much intact peptide reaches the central nervous system after nasal administration, and how long it persists there, are still unresolved. The compound is best described as an active research subject rather than a settled pharmacological agent.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.
Pharmacokinetic accounts emphasize rapid breakdown. After intravenous dosing the intact peptide disappears from blood within minutes, and nasal delivery produces low but measurable concentrations. Metabolites rather than the parent molecule may account for part of the observed activity, although the relative contribution is unresolved. Dosing in the literature varies widely and no optimal schedule has been agreed. These gaps are regularly cited as a reason the findings have not produced broad clinical adoption beyond the original research setting.
Proposed mechanisms center on neurotrophic signaling rather than on classical melanocortin receptor activation. Rodent experiments have reported shifts in the expression of brain-derived neurotrophic factor and nerve growth factor after administration, together with changes in the associated receptor systems. Several authors argue that the peptide acts largely through its degradation products and their interaction with peptidergic pathways, but this remains a hypothesis rather than a settled finding. No single molecular target has been identified in a way that the field broadly accepts.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C37H51N9O10S | Calculated for the free peptide |
| Molar mass | 813.9 g/mol | Anhydrous free base |
| Peptide class | Synthetic heptapeptide | ACTH(4-10) analogue |
| Parent fragment | ACTH(4-10) | Adrenocorticotropic hormone segment |
| Developmental origin | Institute of Molecular Genetics, Moscow | Work began in the 1980s |
Development is attributed to researchers at the Institute of Molecular Genetics in Moscow during the early 1980s, building on earlier Soviet work with ACTH fragments. Russian regulatory approval followed for intranasal use, and the compound has remained commercially available there for decades. Most published human data originate from Russian and, later, some Eastern European clinical reports, which are not always accessible in English translation. Outside that region the material is generally handled as a research chemical rather than a licensed medicine.
Regulatory status differs sharply between jurisdictions. In Russia the peptide is registered as a prescription nasal preparation, while agencies such as the United States Food and Drug Administration have not approved it for any indication. Products sold elsewhere are typically labeled for laboratory research only, and such labels shift responsibility for safe handling to the purchaser. Because the same name covers pharmaceutical-grade nasal drops and bulk research powder, identity and purity documentation becomes the main practical concern when comparing sources.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Reported pharmacological work centers on neurotrophic signaling, including changes in BDNF and NGF expression in hippocampal tissue in animal models. Human data come largely from studies conducted in Russia, and how well those results generalize to other populations remains an open question. Regulatory status differs sharply by jurisdiction: Semax is a registered prescription medicine in Russia, while it holds no approved marketing status in the United States or the European Union. Outside such jurisdictions it is generally handled as a research chemical, which affects both documentation and quality expectations.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. It was developed as a fragment analog of adrenocorticotropic hormone, modeled specifically on the ACTH(4-10) region. The first four residues reproduce that fragment, while a Pro-Gly-Pro tripeptide is appended at the C-terminus. Work on the compound originated in Russia, where it entered clinical use as an intranasal preparation. Its sequence places it among short regulatory peptides studied for effects on the central nervous system rather than on the adrenal axis.
Identity and purity are confirmed with reversed-phase high-performance liquid chromatography, typically monitored at 214 nanometres where the peptide bond absorbs. Mass spectrometry, either electrospray or MALDI-TOF, verifies molecular mass against the theoretical value and detects truncation or adduct formation. Amino acid analysis and peptide mapping provide additional confirmation when required. The most frequently reported impurities are deletion sequences from incomplete coupling, methionine sulfoxide from oxidation, and dimeric species formed through non-covalent aggregation. Impurity profiles depend strongly on the synthesis and purification route chosen by the producer.
Published research has focused mainly on neurological and cognitive endpoints in animal models, with proposed mechanisms involving brain-derived neurotrophic factor and related signalling pathways. A substantial share of the human data originates from a limited number of research groups, and independent replication in other countries remains sparse. Regulatory status reflects that distribution: the peptide is registered as a medicine in Russia and appears in some neighbouring markets, while elsewhere it is handled as a research chemical without approved therapeutic labelling. Questions about dose-response relationships, long-term effects, and comparability across studies are still open.
Lyophilised powder is normally kept at -20 °C in a desiccated container, with some suppliers recommending -80 °C for long-term archival storage. Repeated freeze-thaw cycles are the most common cause of avoidable loss, so aliquoting before freezing reduces variability between working sessions. Dissolved peptide is far less stable than the dry solid and is usually prepared fresh or held briefly at 4 °C. Aqueous solutions support both hydrolysis of the backbone and oxidation of the N-terminal methionine, and these two routes dominate degradation under ordinary laboratory conditions.
=== PCNA-PIDDosome === In addition to the signaling pathways previously discussed, PIDD1 is essential for translesion DNA synthesis (TLS), which allows for DNA extension across damaged regions in response to UV radiation. Within the nucleus, PIDD1 has been observed to associate with critical components of the replication machinery, such as proliferating cell nuclear antigen (PCNA) and replication factor C subunits RFC4 and RFC5, forming a complex referred to as the PCNA-PIDDosome. These proteins were identified as interacting partners of overexpressed PIDD1 through mass spectrometry analysis. PCNA functions as a DNA-sliding clamp that depends on replication factor C (RFC) for its correct positioning on DNA and is crucial for loading DNA polymerases during the replication process. Additionally, PCNA is essential for various DNA repair activities. Importantly, the interactions among [8PIDD]]1, PCNA, and RFC5 are facilitated by their ZU5 domains. As a result, this complex can only form with full-length PIDD1 or, due to the limited availability of full-length PIDD1 and the preferential nuclear localization of its primary autoprocessing product, with PIDD-C.
Concentrations of taste buds vary from species to species, with bullhead catfish having 25 buds in a square millimeter of barbel skin. Barbels begin to develop during the embryonic, larval, or juvenile life stages of most of the species in which they are present. Development regulation of barbels has been linked to the C-C motif ligand 33 of the chemokine family of genes, due to its presence in barbeled catfish and zebrafish and absence or difference in expression in barbel-less members of the same families. This class of genes are signalling genes that provide migrating cells directional information during morphogenesis.
=== Applications === Libraries of peptide aptamers have been used as "mutagens", in studies in which an investigator introduces a library that expresses different peptide aptamers into a cell population, selects for a desired phenotype, and identifies those aptamers that cause the phenotype. The investigator then uses those aptamers as baits, for example in yeast two-hybrid screens to identify the cellular proteins targeted by those aptamers. Such experiments identify particular proteins bound by the aptamers, and protein interactions that the aptamers disrupt, to cause the phenotype. In addition, peptide aptamers derivatized with appropriate functional moieties can cause specific post-translational modification of their target proteins, or change the subcellular localization of the targets.
The ability to purify DNA from a sample is important for many modern biotechnology processes. However, samples often contain nucleases that degrade the target DNA before it can be purified. It has been shown that DNA fragments will partition into the light phase of a polymer–salt separation system. If ligands known to bind and deactivate nucleases are incorporated into the polymer phase, the nucleases will then partition into the heavy phase and be deactivated. Thus, this polymer–salt system is a useful tool for purifying DNA from a sample while simultaneously protecting it from nucleases.
=== Financial operations === It is difficult to trace the financial movements of the CJNG given its multifaceted and illegal nature, but some estimate their assets to be worth over $20 billion. The main source of revenue for the cartel is the trade of illegal drugs, which is extremely profitable with markets in the United States and the EU. Money laundering through real estate investments, front businesses, cryptocurrency, and offshore financial institutes help the CJNG to disguise and distribute large sums. Key to the cartel's large revenue gains is its rapid geographic expansion; the CJNG has captured key ports of entry along the Gulf and the Pacific since its rise in 2009, increasing its ability to extract key elements of the illegal drug supply chain. Although the CJNG generates significant revenues from narco-trafficking, the takeover of non-drug related industries, which often capitalize on the expertise of local gangs who have been absorbed by the CJNG, help the cartel to create more immediate revenues and establish regional control. A variety of peripheral operations, such as extortion of tortilla, avocado, lime, and chicken industries, as well as fuel theft and counterfeit time-share dealings, help the CJNG to accumulate revenue to fund the trafficking of illegal drugs like fentanyl, cocaine, and methamphetamine into the United States. The cartel relies on the extortion of agricultural farms, recently profiting greatly off of Mexico's 'green gold', avocados.
Sources: en.wikipedia.org
Alkanes experiences intermolecular van der Waals forces. The cumulative effects of these intermolecular forces give rise to greater boiling points of alkanes. Two factors influence the strength of the van der Waals forces:
== History == In June 1959, several American pharmacologists convened at Wayne State University in Detroit to discuss a newly discovered structural analogue of meprobamate. The substitution of one hydrogen atom with an isopropyl group on one of the carbamyl nitrogens was intended to yield a drug with new pharmacological properties. It had been developed by Frank Berger at Wallace Laboratories and was named carisoprodol. Building on meprobamate's pharmacological effects, carisoprodol was intended to have better muscle relaxing properties, less potential for addiction, and a lower risk of overdose. Carisoprodol's effect profile did indeed turn out to differ significantly with respect to meprobamate, with carisoprodol possessing stronger muscle relaxant and analgesic effects.
==== Sexual misconduct and resignation ==== A $279,000 payoff for the silence of Jessica Hahn, who alleged that Bakker and former PTL Club co-host John Wesley Fletcher drugged and raped her, was paid with PTL funds through Bakker's associate Roe Messner. Bakker, who made PTL's financial decisions, allegedly kept two sets of books to conceal accounting irregularities. Reporters for The Charlotte Observer, led by Charles Shepard, investigated PTL's finances and published a series of articles. On March 19, 1987, after the disclosure of a payoff to Hahn, Bakker resigned from PTL. Although he acknowledged that he had a sexual encounter with Hahn at a hotel room in Clearwater, Florida, he denied raping her. Bakker was also the subject of homosexual and bisexual allegations made by Fletcher and PTL director Jay Babcock, which Bakker denied under oath. Rival televangelist John Ankerberg appeared on Larry King Live and made several allegations of moral impropriety against Bakker, which both Bakkers denied. Bakker was succeeded as PTL head by the Rev. Jerry Falwell of Thomas Road Baptist Church in Lynchburg, Virginia. Bakker chose Falwell as his successor because he feared that fellow televangelist Jimmy Swaggart, who had initiated an Assemblies of God investigation into Bakker's sexual misconduct, was attempting to take over his ministry. Bakker believed that Falwell would temporarily lead the ministry until the scandal died down, but on April 28, 1987, Falwell barred Bakker from returning to PTL.
In Chadwick's words, "...In order to explain the great penetrating power of the radiation we must further assume that the particle has no net charge..." The existence of the neutron was first postulated by Rutherford in 1920, and in the words of Chadwick, "...how on earth were you going to build up a big nucleus with a large positive charge? And the answer was a neutral particle." Subsequently, he communicated his findings in more detail. In the words of Richard Rhodes, referring to the neutron, "It would therefore serve as a new nuclear probe of surpassing power of penetration." Philip Morrison stated, "A beam of thermal neutrons moving at about the speed of sound...produces nuclear reactions in many materials much more easily than a beam of protons...traveling thousands of times faster." According to Rhodes, "Slowing down a neutron gave it more time in the vicinity of the nucleus, and that gave it more time to be captured." Fermi's team, studying radiative capture which is the emission of gamma radiation after the nucleus captures a neutron, studied sixty elements, inducing radioactivity in forty. In the process, they discovered the ability of hydrogen to slow down the neutrons. Enrico Fermi and his colleagues in Rome studied the results of bombarding uranium with neutrons in 1934. Fermi concluded that his experiments had created new elements with 93 and 94 protons, which the group dubbed ausenium and hesperium.
Sources: en.wikipedia.org
Semax is based on the ACTH(4-10) fragment, a seven-amino-acid segment of adrenocorticotropic hormone. The synthetic peptide retains the core sequence while removing regions associated with endocrine activity. This modification is intended to isolate effects on the nervous system.
It is registered for clinical use in Russia and a few other countries, typically as a nasal drop formulation. It does not hold approval from the United States Food and Drug Administration or the European Medicines Agency. Outside those markets it is generally handled as a research chemical.
The compound was developed in Moscow and the earliest studies were conducted there, so the primary literature is largely in Russian-language journals. Translation and indexing have been incomplete, which limits access for outside researchers. Independent groups have since published some work, but the total volume remains modest.
The main proposal is modulation of neurotrophic factors such as brain-derived neurotrophic factor, supported largely by animal experiments. Receptor-level targets have not been firmly established. Most reviews describe the mechanism as only partially characterized.